


Market Data

Genetic Technologies	
Nasdaq: GENE	
ASX: GTG	
Fiscal Year	June
Industry	Medical Diagnostics
Recent Price	\$2.17
Market Cap	\$33.4M
ADS Out.	15.4M
Avg. Volume (30-day)	152,672
Cash (mrq)	\$21M
Debt (mrq)	\$0
<i>As of December 22, 2021</i>	
gtglabs.com	

Company Overview

Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company's lead products, 'GeneType for Breast Cancer' and 'GeneType for Colorectal Cancer', are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company's commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.



Value Proposition


Dual-listed on Nasdaq and ASX, Genetic Technologies' patented tests are designed to predict an individual's risk of developing chronic disease, enabling early detection and reducing the need for expensive, late-stage care. Chronic disease accounts for an estimated 84% of global healthcare spending, which is expected to reach \$8.7 trillion by 2020. The Company has brought three tests to market and its development pipeline includes its game-changing Multi-Test, which covers up to 70% of mortalities and morbidities. Through its August 2021 acquisition of EasyDNA, Genetic Technologies has significantly accelerated its entrance into the multi-billion-dollar consumer genomics market. In addition to an established revenue stream (\$4.6M in CY20), EasyDNA provides Genetic Technologies the opportunity to leverage an existing global direct-to-consumer marketing channel (operating 70 websites servicing 40 countries).

Commercialization Pathways

Medical – Business to Business (B2B)

Consumer initiated testing (CIT) with medical supervision

Direct to consumer testing (DTC) with no medical supervision



Investment Highlights

- **Leader in the development and commercialization of genetic risk assessment tests**
 - Launched new 'GeneType' tests for breast and colorectal cancer
 - Tests allow providers to target limited resources to patients most in need
 - First-to-market clinical application; most genetic testing remains non-clinical and consumer oriented (genealogy, paternity, etc.)
 - Soft launch in US began in Q1 2020; full online sales began in Q3 2020
 - Launched COVID-19 risk test in 2021; partnered with Infinity BiologiX for US sales
 - Forecast 2QFY22₁ cash receipts +112% versus the prior quarter (1QFY22) to A\$1.8M following the completed integration of EasyDNA in the quarter ₁projected cash receipts
- **Acquired EasyDNA in August 2021**
 - Provides for global expansion in consumer genomics in 40 countries with established sales platform and infrastructure
- **Robust development pipeline**
 - Developing revolutionary Multi-Test; companion diagnostic helps identify risk of serious disease for up to 70% of mortalities and morbidities
 - First phase of launch to include breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease, and Type 2 diabetes; second phase of launch to add melanoma, pancreatic cancer, and atrial fibrillation
- **Respected collaborators accelerate development and validate clinical use**
 - Collaborations led to NHMRC grant (Australia's leading medical research funding organization)
 - Research collaborations with Memorial Sloan Kettering Cancer Center and University of Cambridge announced in February 2019
 - Multi-year agreement with The Translational Genomics Research Institute
- **Global opportunity; initially targeting US, Australia, and China**
 - Global healthcare spending expected to reach \$8.7 trillion by 2020